Sotorasib cracks "undruggable" KRAS (2019-2021)
Amgen's sotorasib was the first drug to successfully target KRAS, a protein that had resisted drug discovery for four decades. It binds the G12C variant and locks the protein in its inactive state. The Food and Drug Administration approved it in May 2021 for previously treated KRAS G12C lung cancer.
Patients who had run out of options responded, and the approval opened the KRAS field to dozens of competing programs.
Responses typically lasted months rather than years, because tumors reactivate the signaling pathway. That resistance is the problem degraders were built to solve.
PT0253's most striking result came from patients who had already progressed on a KRAS-targeted drug, the exact failure mode sotorasib exposed.
